Dianthus Therapeutics, Inc. (DNTH)
(Delayed Data from NSDQ)
$28.83 USD
+0.06 (0.21%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $28.83 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Dianthus Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 174 | 112 | 177 | 149 | 146 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 4 | 4 | 3 | 4 |
Total Current Assets | 177 | 116 | 181 | 152 | 150 |
Net Property & Equipment | 0 | 6 | 7 | 8 | 10 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 2 | 2 | 2 | 2 |
Total Assets | 179 | 147 | 190 | 162 | 162 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 2 | 3 | 4 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 7 | 8 | 8 | 8 | 11 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 10 | 15 | 11 | 11 | 14 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 0 | 6 | 6 | 6 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 11 | 41 | 17 | 18 | 20 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 258 | 508 | 498 | 398 | 321 |
Retained Earnings | -89 | -402 | -326 | -254 | -180 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 169 | 106 | 173 | 144 | 141 |
Total Liabilities & Shareholder's Equity | 179 | 147 | 190 | 162 | 162 |
Total Common Equity | 169 | 106 | 173 | 144 | 141 |
Shares Outstanding | 14.80 | 3.70 | 3.60 | 3.00 | 2.40 |
Book Value Per Share | 11.41 | 28.64 | 47.96 | 47.97 | 58.83 |
Fiscal Year End for Dianthus Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 361 | 377 | 174 | 190 | 78 |
Receivables | 2 | 1 | 0 | 1 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 3 | 3 | 1 | 1 |
Total Current Assets | 366 | 381 | 177 | 191 | 79 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 3 | 1 | 1 | 0 | 0 |
Total Assets | 369 | 382 | 179 | 192 | 79 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 3 | 3 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 6 | 6 | 7 | 11 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 10 | 9 | 10 | 13 | 4 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 1 | 1 | 1 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 11 | 10 | 11 | 14 | 4 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 479 | 476 | 258 | 257 | 509 |
Retained Earnings | -121 | -103 | -89 | -79 | -434 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 358 | 373 | 169 | 178 | 75 |
Total Liabilities & Shareholder's Equity | 369 | 382 | 179 | 192 | 79 |
Total Common Equity | 358 | 373 | 169 | 178 | 75 |
Shares Outstanding | 29.30 | 29.30 | 14.80 | 14.80 | 3.70 |
Book Value Per Share | 12.23 | 12.72 | 11.41 | 12.05 | 20.16 |